Tyrosine Kinase Inhibitor Therapy-Induced Changes in Humoral Immunity in Patients With

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Supplementary appendix

Table of contents

Supplementary Figures 2

Supplementary Figure 1 2

Supplementary Figure 2 3

Supplementary Figure 3 4

Supplementary Figure 4 5

Supplementary Figures

Supplementary Figure 1

Supplementary Figure 1. The Ig levels of separate CML patients during the follow-up.

The patients shown in red colour had ≥2 Ig values below the lower limit of normal.

Supplementary Figure 2

Supplementary Figure 2. Mean Ig levels between patients with or without hypogammaglobulinemia during the follow-up (hypogammaglobulinemia defined as ≥2 Ig values below the lower limit of normal during the follow-up). I-bars represent SD. Statistical analysis was done with two-way ANOVA.

Supplementary Figure 3

Supplementary Figure 3. Higher Sokal score was associated with lowered Ig levels.

All CML patients were divided into three groups based on the Sokal score. Mean IgA (A), IgG (B) and IgM (C) levels at different timepoints are shown. I-bars represent SD. Statistical analysis was done with two-way ANOVA.

Supplementary Figure 4

Supplementary Figure 4. The analysis of of TKI treatment response with Ig levels and B cell dynamics.

All CML patients were divided into two groups based on the achievement of MMR (BCR-ABL ≤0.1% on the International scale (IS)) at 12 months timepoint. Mean Ig levels are shown. I-bars represent SD. Statistical analysis was done with two-way ANOVA.

1